USPTO serial 79399244
ANGICYTE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 24, 2025
- Examiner
- JANSON, ANDREW KYLE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ANGICYTE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Usha Menon
Usha Menon D'Ambrosio & Menon, PLLC3 Sugar Creek Center Blvd.Suite 100Sugar Land, TX 77478Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Stem cells for research purposes; stem cells for scientific purposes; chemicals for use in manufacturing pharmaceuticals; reagents for research purposes; reagents for medical research; reagents for scientific purposes; diagnostic reagents for scientific or research use; cell culture reagents for scientific and research use; blood culture media for scientific use | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of ischemic diseases; Drugs for medical purposes, namely, pharmaceutical preparations for the treatment of ischemic diseases; Pharmaceutical preparations containing stem cells for the treatment of ischemic diseases and stimulation of vascular regeneration, blood vessel repair, and tissue revitalization; Stem cells for medical purposes; cells for medical use; cell growth media for growing cells for medical use; living cells for medical use; cellular function activating agents for medical purposes; Vaccines; Reagents for medical use; medical diagnostic reagents | ACTIVE | — |
| 010 | Medical devices for the treatment of ischemic diseases and stimulation of vascular regeneration, blood vessel repair, and tissue revitalization; Medical apparatus and instruments for the treatment of ischemic diseases and stimulation of vascular regeneration, blood vessel repair, and tissue revitalization; Apparatus for the regeneration of stem cells for medical purposes; medical devices and apparatus for vascular regeneration and repair in the treatment of ischemic diseases; Medical devices and apparatus for cell therapy for the treatment of ischemic diseases and stimulation of vascular regeneration, blood vessel repair, and tissue revitalization; Blood testing apparatus | ACTIVE | — |
| 042 | Medical and pharmacological research services; Stem cell research; Scientific research services for others relating to the isolation and cultivation of human tissues and cells; Research in the field of cell engineering technology; Scientific and medical research in the field of vascular regeneration and repair; Research and development of medicines; Pharmaceutical drug development services; Drug discovery services; Development of pharmaceutical preparations and medicines; Development of stem and progenitor cell therapies and other cell therapies; Research and development services in the medical field of cell therapy; research and development services in the medical field of vascular regeneration and repair; Scientific research in the nature of conducting clinical trials for others; Blood analysis services for scientific research purposes | ACTIVE | — |
| 044 | Regenerative medicine services; medical services; stem cell therapy services; cell therapy services; Stem cell therapy services for vascular regeneration and repair; cell therapy services relating to the generation of human vascular reparative cells; cell therapy services relating to the injecting, grafting or implanting of cells into patients; medical services relating to the removal, treatment and processing of cells; Medical services relating to the removal, treatment and processing of stem cells; Stem cell storage, namely, stem cell bank services; Cultured cell bank services for medical transplantation; medical laboratory services for the analysis of samples taken from patients; Medical analysis services for the diagnosis and treatment of persons; Services for the testing of blood, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical services relating to the removal, treatment and processing of human blood | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by VASCVERSA LIMITED
- Other trademarks owned by VASCVERSA LIMITED
- Other trademarks owned by VASCVERSA LIMITED
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ANGICYTE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 12, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 19, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 5, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 21, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 21, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 18, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 3, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 3, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 24, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 11, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 24, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 24, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 6, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 6, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 30, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 7, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 13, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 13, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 13, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 12, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 21, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 20, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 19, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 18, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 11, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 11, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 4, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |